Abstract
131I chimeric L6 (ChL6) monoclonal antibody (MoAb) therapy has been performed in 12 patients with advanced, metastatic breast cancer. The protocol was designed to determine the maximum tolerated dose (MTD) of radioimmunotherapy that could be administered at 4 intervals. Ten patients received 20 - 70 mCi/m2 of 131I ChL6. Two of the patients received granulocyte colony stimulating factor (GCSF) on days 10-20 post therapy. The MTD for two doses was 60 mCi/m2 and thrombocytopenia was the dose limiting toxicity in the absence of marrow reconstitution with stem cells. Two patients received 150 mCi/m2 with autologous peripheral blood stem cell support 7 and 9 days post treatment. The MTD has not been reached for 131I-ChL6 with autologous stem cell support. In the 12 patients treated with 131I ChL6, six patients (50%) had measurable tumor regressions greater than 30% of the sum of the largest two dimensional products for measurable tumors. Four of these 6 patients had a partial response (PR), i.e., ≤ 50% reduction in tumor size.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
I.C. Henderson, J.R. Harris, D.W. Kinne, and S. Hellman. Cancer of the breast, in: V.T. Devita, S. Hellman, S.A. Rosenberg, eds., Cancer Principles and Practice of Oncology. JB Lippincott, Philadelphia 1197–1261 (1989).
E. Silverberg, C.C. Boring, and T.S. Squires. Cancer statistics. CA 40:9–26 (1990).
K.H. Antman. Dose intensive therapy in breast cancer, in: “High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cell,” J.O. Armitage, K.H. Antman, eds., Williams & Wilkins, Baltimore 701–718 (1992).
M.S. Fox. On the diagnosis and treatment of breast cancer. JAMA 241:489–494 (1979).
J J. Tjandra and I.F.C. McKenzie. Murine monoclonal antibodies in breast cancer: an overview. Br J Surg 75:1067–1077 (1988).
A. Thor, M.O. Weeks, and J. Schlom. Monoclonal antibodies and breast cancer. Seminars in Oncology 13:393–401 (1986).
L.M. Weiner, J. O’Dwyer, J. Kitson, R.L. Comis, A.E. Frankel, R.J. Bauer, M.S. Konrad, and E.S. Groves. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res 49: 4062–4067 (1989).
J. Malamitsi, D. Skarlos, S. Fotiou, P. Papakostas, G. Aravantinos, D. Vassilarou, J. Taylor-Papadimitriou, K. Koutoulidis, G. Hooker, and D. Snook. Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies. J Nucl Med 29:1910–1915 (1988).
B.J. Gould, M.J. Borowitz, E.S. Groves, P.W. Carter, D. Anthony, L.M. Weiner, and A.E. Frankel. Phase I study of antibreast immunotoxin by continuous infusion. J of the NCI 81:775–781 (1989).
B.P. Avner, S.K. Liao, B. Avner, K. DeCall, and R.K. Oldham. Therapeutic murine monoclonal antibodies developed for individual cancer patients. J of Biological Resp Mod 8:25–36 (1989).
S.J. DeNardo, L.F. O’Grady, D.J. Macey, L.A. Kroger, G.L. DeNardo, K.R. Lamborn, N.B. Levy, S.L. Mills, I. Hellstrom, and K.E. Hellstrom. Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Nucl Med Biol 18:621–631 (1991).
S.J. DeNardo, G.R. Mirick, L.A. Kroger, L.F. O’Grady, K.L. Erickson, A. Yuan, K.R, Lamborn, I Hellstrom, K.E. Hellstrom and G.L. DeNardo. The biologic window for ChL6 radioimmunotherapy. Cancer (1994).
I. Hellstrom, D. Horn, P. Linsley, J. P. Brown, V. Brankovan, and K.E. Hellstrom. Monoclonal antibodies raised against human lung carcinomas. Cancer Res 46:3917–3923 (1986).
I. Hellstrom, P.L. Beaumier, and K.E. Hellstrom. Antitumor effects of L-6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Science USA 83: 7059–7063 (1986).
G.P. Adams, S.J. DeNardo, A. Amin, L.A. Kroger, G.L. DeNardo, I. Hellstrom, and K.E. Hellstrom. Comparison of the pharmacokinetics in mice and the biological activity of murine L-6 and human-mouse chimeric Ch L6 antibody. Antibod Immunoconjug Radiopharm 5:81–95 (1992).
A.Y. Liu, R.R. Robinson, K.E. Hellstrom, E.D. Murray, Jr., C.P. Chang, and I. Hellstrom. Chimeric mouse-human IgGl antibody that can mediate lysis of cancer cells. Proc Natl Acad Science USA 84:3439–3443 (1987).
W.M. Hunter and F.C. Greenwood. Preparation of iodine-131 labelled growth hormone of high specific activity. Nature 194:495 (1962).
S.L. Mills, S.J. DeNardo, G.L. DeNardo, A.L. Epstein, J-S. Peng, and D. Colcher. I-123 radiolabelling of monoclonal antibodies for in vivo procedures. Hybridoma 5:265–275 (1986).
P.L. Beaumier, D. Neuzil, H-M. Yang, E.A. Noll, R. Kishore, J.F. Eary, K.A. Krohn, W.B. Nelp, K.E. Hellstrom, and I. Hellstrom. Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J Nucl Med 27: 824–828 (1986).
D J. Macey, G.L. DeNardo, and S J. DeNardo. A treatment planning program for radioimmunotherapy. Front Radiat Ther Oncol 24:123–131 (1990).
A. Louderback, E.H. Mealy, and P.H. Wiernik. A new dye-binding technique using bromocresyl purple for determination of albumin in serum. Clin Chem 14:793–794 (1968).
P. Yam L.D. Petz, and N.R. Cooper. The relationship between hemolytic and immunodiffusion methods for measurement of C4 in patients with immunologic disorders. Am J Clin Path 64:351–357 (1975).
A. Linde, B. Anderson, S.B. Svenson, H. Ahrne, M. Carlsson, P. Forsberg, et al. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infec Dis 165:994–1000 (1992).
A. Kessinger, J.O. Armitage, J.D. Landmark, D.M. Smith, and D.D. Weisenberger. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 71:723–727 (1988).
A. Elias, L. Ayash, K. Anderson, C. Wheeler, G. Schwartz, I. Teppler, C. Lynch, M. Hunt, S. Pap, J. Deary, J Pelaez, L. Schnipps, J Griffin, E. Frei, and K. Antman. Hematologic support during high dose intensification for breast cancer: Recruitment od peripheral blood progenitor cells by GM-CSF and chemotherapy. Blood 76 (suppl):536a (1990).
S.J. DeNardo, K.A. Warhoe, L.F. O’Grady, G.L. DeNardo, I. Hellstrom, K.E. Hellstrom, and S.L. Mills. Radioimmunotherapy with 1-131 chimeric L-6 in advanced breast cancer, in: “Breast Epithelial Antigens,” R.L. Ceriani, eds., Plenum Press, New York, pp. 227–232 (1991).
G.E. Goodman, I. Hellstrom, C. Nicaise, L. Brodzinsky, D. Hummel, and K.E. Hellstrom. Phase I trial of murine monoclonal antibody L-6 in breast, colon, ovarian,and lung cancer. J Clin Oncol 50:2449–2454 (1990).
G.E. Goodman, I. Hellstrom, D.E. Yelton, J.L. Murray, S. O’Hara, E. Meaker, L. Zeigler, P. Palazollo, C. Nicaise, J. Usakewicz, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L-6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 36(4):267–273 (1993).
G.L. DeNardo, S.J. DeNardo, N. Levy. Treatment of B cell malignancies with 131I-Lym-l and mechanisms for improvement. in: “Monoclonal Antibodies 2, Applications in Clinical Oncology,” A. Epenetos, ed., Chapman & Hall Medical, New York, pp. 355–367 (1993).
J.A. Ledermann, R.H.J Begent, K.D. Bagshawe, S.J. Riggs, F. Searle, M.G. Glaser, AJ. Green and R.G. Dale. Repeated antitumor antibody therapy in man with suppression of the host response by cyclosporin A. Brit J Cancer 58: 654–657 (1988).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
DeNardo, S.J., O’Grady, L.F., Richman, C.M., DeNardo, G.L. (1994). Overview of Radioimmunotherapy in Advanced Breast Cancer Using I-131 Chimeric L6. In: Ceriani, R.L. (eds) Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment. Advances in Experimental Medicine and Biology, vol 353. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2443-4_19
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2443-4_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6038-4
Online ISBN: 978-1-4615-2443-4
eBook Packages: Springer Book Archive